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Background: The pathogenesis of pulmonary hypertension (PH) in hemodialysis is still unclear. The aim of this
study was to identify the risk factors associated with the presence of PH in chronic hemodialysis patients and to
verify whether these factors might explain the highest mortality among them.
Methods: We conducted a retrospective study of hemodialysis patients who started treatment from August 2001
to October 2007 and were followed up until April 2011 in a Brazilian referral medical school. According to the
results of echocardiography examination, patients were allocated in two groups: those with PH and those without
PH. Clinical parameters, site and type of vascular access, bioimpedance, and laboratorial findings were compared
between the groups and a logistic regression model was elaborated. Actuarial survival curves were constructed and
hazard risk to death was evaluated by Cox regression analysis.
Results: PH> 35 mmHg was found in 23 (30.6%) of the 75 patients studied. The groups differed in extracellular
water, ventricular thickness, left atrium diameter, and ventricular filling. In a univariate analysis, extracellular water
was associated with PH (relative risk = 1.194; 95% CI of 1.006 – 1.416; p = 0.042); nevertheless, in a multiple model,
only left atrium enlargement was independently associated with PH (relative risk =1.172; 95% CI of 1.010 – 1.359;
p = 0.036). PH (hazard risk = 3.008; 95% CI of 1.285 – 7.043; p = 0.011) and age (hazard risk of 1.034 per year of age;
95% CI of 1.000 – 7.068; p = 0.047) were significantly associated with mortality in a multiple Cox regression analysis.
However, when albumin was taken in account the only statistically significant association was between albumin
level and mortality (hazard risk = 0.342 per g/dL; 95% CI of 0.119 – 0.984; p = 0.047) while the presence of PH lost its
statistical significance (p = 0.184). Mortality was higher in patients with PH (47.8% vs 25%) who also had a
statistically worse survival after the sixth year of follow up.
Conclusions: PH in hemodialysis patients is associated with parameters of volume overload that sheds light on its
pathophysiology. Mortality is higher in hemodialysis patients with PH and the low albumin level can explain this
association.
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Pulmonary hypertension (PH) comprises a group of
clinical and pathophysiological entities with similar fea-
tures due to a great variety of underlying conditions
[1,2]. Chronic renal disease is one of these causes [3]
but the pathogenesis of PH in this group of patients is
still unclear. Hemodialysis patients are exposed to con-
tinuous pulmonary insults of multifactorial origin, such
as hormonal and metabolic derangement associated
with end-stage terminal disease, which may induce
pulmonary vascular alterations and consequent
increased resistance. Besides, high serum level of acute
phase reactive protein and cytokines, including IL-1β,
TNF-α and IL-6 have been demonstrated in this popu-
lation suggesting that chronic inflammation might have
some role in the pathogenesis of PH in patients under-
going hemodialysis [4]. On the other side, PH can
cause right ventricular failure with clinical manifesta-
tions of systemic venous congestion, pleural effusion,
and ascites [1] which might also result in reduced
systemic arterial pressure and intradialytic hypotension
[2,5]. In fact, renal transplantation, by restoring nor-
mal renal function, is one of the most effective
choices of treatment for PH in end-stage renal disease
patients [6].
PH has been associated with poor survival in
hemodialysis patients [3,6-9]. However, data regarding
the prevalence and the influence of others factors that
can affect the survival of PH patients with end-stage
renal disease are limited. Hence, the aim of this study is
to identify the risk factors associated with the presence
of PH in hemodialysis patients and to verify whether
these factors might explain the highest mortality among
these patients.Methods
We retrospectively collected demographic, clinical, and
laboratorial data from the charts of hemodialysis
patients of the Division of Nephrology of the University
Hospital of the Botucatu School of Medicine, State Uni-
versity of São Paulo, Brazil. Patients had started treat-
ment from August 2001 to October 2007 and were
followed up until April 2011. All patients had at least
one monthly appointment with their nephrologists at
the hospital’s clinics.
The inclusion criteria were patients older than 18
years, in the hemodialysis program for over two months,
who had a good technical quality echocardiography
examination. The exclusion criteria were the presence
of ventricular dyskinesias and/or hemodynamically
significant valvar disease, alcoholics, psychiatric patients,
carriers of hepatic cirrhosis and/or malignant
neoplasms.The Research Ethical Committee of the Botucatu
Medical School approved the study and granted a waiver
for informed consent (no 3374/09), since it was only a
survey of charts.
Demographic and clinical data (comorbidities, type
and location of vascular access and bioimpedance)
were recorded. Results of blood tests for hematocrit,
C-reactive protein, creatinine, albumin, calcium, phos-
phorus, and parathyroid hormone levels were also col-
lected. All the results recorded were from exams
performed at the beginning of the midweek hemodialysis
within at least two weeks before or after the echocardiog-
raphy study.
Based on this examination, patients were allocated in
two groups: PH group, formed by patients echocardio-
graphycally diagnosed as having PH, and non PH
group, formed by patients with no PH. Clinical and
laboratorial findings between these two groups were
compared.
Echocardiographic imaging was performed according
to a previously standardized technique [10,11] by
highly skilled echocardiographers using a Sonos 2000
(Hewlett Packard) equipment attached to a multifre-
quential 2.5- to 3.5-MHz transducer. The coefficient of
variation of echocardiographic measurements in our la-
boratory was 2.5 %. The following data were regis-
tered: diameters of the left ventricular (LV) cavity at
systole and diastole; thickness of the posterior wall and
the septum, both at diastole and systole, left atrium
and aorta at systole; systolic volume; early peak of mi-
tral flow velocity (E wave); atrial peak filling velocity
(A wave). These data were used to calculate the rela-
tive thickness of the left ventricle, the left atrium/aorta
diameter ratio, the E/A relationship, the LV mass, and
LV mass index (LVMI). In case of absence of tricuspid
regurgitation, a relationship between time with peek
flow/time of right ventricular ejection inferior to 0.3
was defined as PH [12]. When tricuspid regurgitation
was identified with continuous wave Doppler, systolic
pulmonary arterial pressure was calculated using a
validated equation: SPAP=4 X (tricuspid systolic jet)2 + 10
mmHg (estimated right atrial pressure) [10]. PH was
defined as a systolic pulmonary arterial pressure equal or
higher than 35 mmHg [10,11].
Monofrequencial electric bioimpedance (800 μA and
50 kHz) was performed with Biodynamics 450 device
(BiodynamicsW, USA) after the end of hemodialysis, with
the patients in the supine position. Patient’s assessments
were conducted using a connection between the analyzer
to the back of the hand and instep of the subject. Resist-
ance and reactance were measured; phase angle, total
body water (TBW), intra (ICW) and extracellular water
(ECW) were calculated based on resistance and react-
ance. Then a microprocessor uses the stored values to
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ing equations:
Phase angle ¼ arc tangent tan1 
of reactance=resistance 13 ;½
Total body water ¼ height2=resistance þ b weightð Þ
þ c ageð Þ þ d 14 ;½
Intracellular water ¼ a height2  reactance=resistance2 
þ b weightð Þ þ c ageð Þ þ d 15 ;½
Extracellular water ¼ total body water
 intracellular water 15 ;½
Leanbodymass ¼ a height2 þ b weightð Þ þ c ageð Þ
þ d resistanceð Þ þ e 13½ ;
Fatmass ¼ weight fat freemass 13 ;½
Variables a, b, c, d, and e represent constant coeffi-
cients calculated by regression analysis in each instance
according to references [13-15].
Data analysis
Normally distributed variables were described as mean
and standard deviation and the frequencies as percent-
age. Variables not normally distributed were described as
median and interquartile interval.
The clinical characteristics evaluated at the beginning
and at the end of follow-up within groups were com-
pared by paired t-test; the comparisons between PH
group and non-PH group were performed by t-test for
unpaired samples, qui-square, or Mann–Whitney test, as
appropriate.
Variables with a >10% difference between the two
groups were selected for multivariate Cox proportional
risk regression analysis. Categorical variables were coded
as presence (1) or absence (0) to be included in the Cox
model. Potential collinearity among variables selected
for multiple analysis were tested and if associations were
present one of the variables was excluded from the Cox
model. Results were considered significant at P < 0.05.
Three Cox models were elaborated: model 1, presence of
PH; model 2, presence of PH, age, sex, body mass index,
presence of smoking, diabetes and/or dyslipidemia, and
systolic blood pressure; model 3, the covariates in model
2 and extracellular water. Primary end point was death
by any cause. Patients followed until April 2011 who did
not reach the end point were censored. Actuarial sur-
vival curves were constructed according to the life table
method and compared by Greenwod method [16]. A lo-
gistic regression model was constructed to evaluate asso-
ciations between presence of PH and its risk factors.Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) version 12.0 (SPSS,
Chicago, IL).
Results
There were 118 hemodialysis patients eligible for this
study, but 43 were excluded for meeting any exclusion
criterion. Table 1 shows the clinical characteristics of the
75 patients, 47 males and 28 females, included in the
study. Their mean age was 56± 12.7 years, there were 53
whites, 16 of them in PH group, 20 afro-descendents,
seven in PH group, and two Asiatics, both in non-PH
group. There were 18 diabetics, six of them in PH group,
51 dyslipidemics, 15 of them in PH group, and 12 smo-
kers, four of them in PH group. The two groups were not
statistically significant different regarding these attributes.
Table 1 also expresses clinical anthropometric and
bioimpedance characteristics of groups. PH group
patients presented both more extracellular mass and
water. The site and type of vascular access did not differ
between groups.
Echocardiographic and laboratorial data are shown in
Table 2. The groups differed in ventricular thickness, left
atrium diameter, and early systolic peak of ventricular
filling.
The associations of PH with left ventricular hyper-
trophy, diastolic dysfunction, and volume status were
assessed by logistic regression. Firstly, in an univariate
analysis, ECW was statistically associated with PH (rela-
tive risk of 1.194; 95% confidence interval of 1.006 –
1.416; p = 0.042). Secondly, including left atrium this
variable was statistically associated with the presence of
PH (relative risk of 1.216; 95% confidence interval of
1.057 – 1.398; p = 0.006) and ECW lost its significance
(p = 0.303). In subsequent models, in which were suc-
cessively included diastolic filing of left ventricle, albu-
min level, and posterior wall thickness only left atrium
maintained statistically significant association with PH
(relative risk of 1.172; 95% confidence interval of 1.010 –
1.359; p = 0.036).
Among the 23 patients with PH there were 11 deaths
(47.8%) while among the 52 patients without PH there
were 13 deaths (25%). Survival table curves concerning
the presence or absence of PH are expressed in Figure 1.
PH patients had a statistically worse survival after the
sixth year of follow up.
Cox regression analysis, which included variables with
p < 0.1 between groups, revealed a statistically significant
association only between albumin levels and mortality
(Table 3).
The Cox model 1, constructed only with the presence
of PH, demonstrated statistically significant association
between PH and mortality (hazard risk of 2.438; 95%
confidence interval of 1.128 – 5.266; p = 0.023). The
Table 1 Clinical and bioimpedance data in groups of hemodialysis patients with and without pulmonary hypertension
Pulmonary Hypertension (n = 23) No Pulmonary Hypertension (n = 52) p
Age (years) 59 ± 11.2 55 ± 13.3 0.189
Male/Female 16/ 29/ 0.385
White/non White 9/14 18/34 0.909
BMI (Kg/m2) 24.9 ± 3.86 24.4 ± 5.08 0.695
Vascular access 0.777
Radial autologous 18 34
Brachial autologous 1 5
Radial graft 1 5
Femoral graft 2 4
Catheter 1 4
IWG (kg) 2.2 (2.0-3.2) 2.8 (2.2-3.4) 0.229
SBP (mm Hg) 142± 17.2 147± 14.0 0.221
DBP (mm Hg) 86 ± 9.16 89 ± 8.35 0.131
Phase angle (degree) 6.3 ± 1.2 6.6 ± 1.2 0.243
Capacitance 619.0 ± 194.8 635.2 ± 149.3 0.701
Resistance 582.3 ± 104.1 591.8 ± 87.9 0.691
Reactance 62.8 ± 10.7 69.6 ± 16.7 0.087
Cellular mass (kg) 22.2 ± 5.9 20.5 ± 4.7 0.197
Extracellular mass (kg) 25.8 ± 4.9 22.8 ± 4.9 0.019
LM (kg) 48 ± 10.3 43.3 ± 9.0 0.055
FM (kg) 20.7 ± 8.5 20.0 ± 8.7 0.737
ICW (l) 19.1 ± 5.0 17.6 ± 3.7 0.175
ECW (l) 15.7 ± 2.6 14.0 ± 3.2 0.032
TBW (l) 0.857 ± 0.184 0.811± 0.176 0.317
ECW/TBW (%) 34.8 ± 6.9 31.668± 6.0 0.055
BMI: body mass index; IWG: interdialytic weight gain; SBP: systolic blood pressure; DBP: diastolic blood pressure; LM: lean body mass; FM: fat mass; ICW:
intracellular water; ECW: extracellular water; TBW: total body water.
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mass index, presence of smoking, diabetes mellitus and/
or dyslipidemia, and systolic blood pressure, revealed a
statistically significant association between both PH and
mortality (hazard risk of 3.008; 95% confidence interval
of 1.285 – 7.043; p = 0.011) and age and mortality (haz-
ard risk of 1.034 per year of age; 95% confidence interval
of 1.000 – 7.068; p = 0.047). The model 3, elaborated
with all these covariates and extracellular water, showed
a statistically significant association between PH and
mortality (hazard risk of 3.164; 95% confidence interval
of 1.267 – 7.900; p = 0.014) and a marginally association
between age and mortality (hazard risk of 1.034 per year
of age; 95% confidence interval of 0.999 – 1.071;
p = 0.055). In this last model, any other covariate pre-
sented significant association with mortality. When PH
was included with albumin, only albumin retained statis-
tical significance (hazard risk of 0.342 per mg/dL; 95%
confidence interval of 0.119 – 0.984; p = 0.047) while the
presence of PH lost its statistical significance (p = 0.184).Discussion
In this cohort of 75 hemodialysis patients, followed up
until 10 years, the frequency of PH, evaluated by echo-
cardiography, was 30.6%. As showed in other studies
[3,6-9] the presence of PH was associated with a poor
prognosis and this fact is accentuated at six years of fol-
low-up. Hemodialysis patients with PH presented differ-
ences in cardiac morphology, clinical, and biochemical
characteristics when compared with no-PH patients.
Cox regression analysis, which included confounding
variables, indicated that the effect of PH on mortality is
independent of age, sex, body mass index, smoking, dia-
betes mellitus, dyslipidemia, systolic blood pressure and
extracellular water. However, when albumin is included
in a model with PH, only albumin retains statistical sig-
nificance while PH lost its significance as a predictor of
mortality. Hence, as lower is the albumin level as higher
is the mortality. Therefore, in the current study, the
prognostic impact of PH on hemodialysis patients
appears to be mediated by lower albumin levels.
Table 2 Echocardiographic and laboratorial data in groups of hemodialysis patients with and without pulmonary
hypertension
Pulmonary Hypertension (n=23) No pulmonary Hypertension (n=52) p
LVIDD (mm) 48.6±5.86 49.0±6.57 0.810
PWT (mm) 12.5±1.72 11.5±1.76 0.016
IVST (mm) 13.0±1.74 11.9±2.26 0.042
LVRWT 0.53±0.109 0.49±0.111 0.087
LVM (g) 309±75.5 277±78.8 0.101
LVMI (g/m2.7) 81.7±23.51 78.4±23.10 0.575
LA (mm) 46.2±4.29 41.9±5.68 0.002
AO (mm) 34.1±4.59 32.5±3.47 0.102
LA/AO 1.4±0.21 1.3±0.20 0.140
E cm/s 81.1±28.57 65.7±28.53 0.042
A cm/s 87.3±23.88 81.0±18.71 0.256
E/A 0.79(0.70-0.94) 0.74(0.55-0.94) 0.224
PTH (pg/ml) 241(117-491) 257(128-481) 0.726
Creatinine (mg/dl) 10.7±3.16 10.9±3.07 0.811
Albumin (g/dl) 3.6±0.36 3.8±0.41 0.082
Calcium (mg/dl) 9.1±0.80 9.0±0.72 0.756
Phosphorus (mg/dl) 4.6±1.74 5.3±1.57 0.134
Ca x P 42.5±16.94 47.3±14.33 0.204
CRP (mg/dL) 0.8 (0.20-1.27) 0.5 (0.10-1.20) 0.633
Ht (%) 33.6±5.54 33.2±4.31 0.707
LVIDD: left ventricular internal diastolic dimension; PWT: posterior wall thickness; IVST: interventricular septum thickness; LVRWT: left ventricular relative wall
thickness; LVM: left ventricular mass; LVMI: left ventricular mass index; LA: left atrium; AO: aorta; E: early peak diastolic flow; A: atrial peak diastolic flow; PTH:
parathyroid hormone; Ca x P: calcium phosphorus product; CRP: C-reactive protein; Ht: hematocrit.
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hemodialysis patients with PH did not evaluated possible
factors, such as albumin or volemic status, that could
interfere on mortality in hemodialysis [3,17-21]. Ygla et al
[8] showed, by multiple analyses, that besides age, PH
was an independent predictor of prognosis, what is inFigure 1 Mortality associated with pulmonary hypertension in hemodaccord with our findings, but their analysis was not
adjusted to any biochemical markers of prognosis.
In the present study, PH was associated with markers
of volume overload: large left atrium and increased
extracellular water. In a multiple logistic regression ana-
lysis, only left atrium diameter retained statisticallyialysis patients.




95.0% CI for HR p-value
Lower Upper
Albumin (g/dL) 0.117 0.019 0.714 0.020
Relative wall thickness 0.039 0.000 3.78 x 102 0.488
Posterior wall (mm) 1.515 0.841 2.730 0.167
Interventricular septum (mm) 1.055 0.587 1.898 0.858
Left atrium (mm) 0.925 0.806 1.060 0.261
Early peak diastolic (cm/s) 0.992 0.971 1.013 0.435
PH (presence/absence) 1.734 0.555 5.415 0.344
ECW/TBW 2.1x103 0.001 4.1x 109 0.299
Intracellular water (L) 0.817 0.582 1.146 0.241
Height (m) 0.996 0.918 1.081 0.932
Reactance (Ω) 0.991 0.937 1.048 0.755
PH: pulmonary hypertension; ECW/TBW: extracellular water/total body water.
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a correlation statistically significant between ECF/TBW
and left atrium diameter (r = 0.33; p < 0.01) (data not
shown). Thus, we hypothesize that volume overload can
be important in the physiopathogenesis of PH observed
in hemodialysis patients. Corroborating this idea, there
are studies that demonstrate higher cardiac output and
lower hemoglobin level in PH hemodialysis patients [17-
19]. In addition, a recent study by Agarwal [9] showed
that left atrial diameter is strongly associated with PH in
hemodialysis patients, fact that might reflect chronic
volume overload. It is noteworthy that our results also
suggest that if right cardiac catheterization had been car-
ried out it possibly would reveal a post-capillary PH
which is known as an important risk factor for poor out-
come of patients with left heart disease [22].
Although some authors have demonstrated that site
and type of vascular access have influence on pulmonary
pressure [17-19], we did not find differences regarding
to this matter. Also, the association of mineral bone
renal disease markers with PH was not observed in the
current study differing from Havlucu et al [17] who
found increased of parathyroid hormone levels in
patients with elevated systolic pulmonary arterial pres-
sure. On the contrary, in accordance with other authors
[9,20,21] our PH and no-PH groups were homogeneous
concerning calcium, phosphorus, and parathyroid hor-
mone levels.
The tendency to lower albumin level in PH group
could be explained by two mechanisms: hemodilution or
inflammation. PH group presented markers of overload
volume, such as higher extracellular volume, evaluated by
bioimpedance, and larger left atrium, while the C-reactive
protein was similar in both groups. As C-reactive protein
levels were not different between groups, we can supposethat albumin was not decreased by microinflammation;
consequently, dilution is the strongest hypothesis to ex-
plain the lower albumin levels in PH group. Besides, we
stress a statistically significant correlation between ECF/
TBW and albumin (r = 0.41 p <0.01) (data not shown).
Therefore, these findings point out to hemodilution as
the presumable mechanism to explain the propensity to
lower albumin level in PH group. Thus, we speculate that
volume overload participates in the genesis of increased
pulmonary arterial pressure in hemodialysis patients. This
physiopathological mechanism of PH might be a peculiar-
ity of chronic kidney disease.
Some limitations must be addressed in the present
study. Firstly, it is the small number of patients in our
series, but our results encourage its reproduction to con-
firm these results in other series. Secondly, PH was iden-
tified only by echocardiography and not confirmed by
right cardiac catheterization. Nevertheless, for ethical
reasons, invasive exams for research objectives are not
justified. In fact, none of previous studies on PH in
hemodialysis patients evaluated pulmonary arterial pres-
sure invasively. Thirdly, the vascular hemodialysis access
flux was not measured; however the local and type of ac-
cess were similar and did not differ statistically between
the two groups.
Conclusion
PH in hemodialysis patients is associated with para-
meters of volume overload that sheds light on its patho-
physiology. Mortality in hemodialysis patients is higher
in PH patients, but in a multiple analysis, low level of al-
bumin could explain this association. For the time being,
our results suggest that considering the scanty prognos-
tic of hemodialysis patients with PH, strict attention
should be taken to avoid volume overload in this popu-
lation. Perhaps, daily or extended dialysis might help to
reach this aim.
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